Sweden Achieves 18-Year Ahead of Schedule Smoke-Free Target

Dec.08.2022
Sweden Achieves 18-Year Ahead of Schedule Smoke-Free Target
Sweden achieves smoking rate of 5.6%, becoming the only European country to reach EU's no smoking goal ahead of schedule.

Swedish authorities have officially confirmed that the smoking rate in Sweden has now decreased to 5.6%. This makes Sweden the only European country to be on track to achieving the EU's goal of becoming smoke-free, achieving this target 18 years ahead of the 2040 deadline.


At an event organized by the Stockholm Snus Nicotine Committee, participants evaluated Sweden's incredible achievements and leadership in the fight against smoking. The country is on track to become the world's first to be defined as "smoke-free" and have a smoking population of less than 5%.


Since the 1980s, Sweden has achieved a remarkable feat unmatched by any other country in the world, reducing its smoking rate from 35% to less than 6%. The country now boasts the second lowest smoking rate in Europe, which is only half that of the next lowest country. In contrast, the average smoking rate in the EU is around 23%, which is four times higher than Sweden's. Notably, Europe also has the lowest tobacco-related death rate in the world.


On November 30, 2022, a group of leading public health experts, consumer advocates, and harm reduction professionals celebrated this achievement in Stockholm and once again called on policymakers around the world to ensure the availability of less harmful smoking alternatives as aids for quitting smoking.


Delon Human, President and Stockholm event organizer of Health Diplomats, stated during the event that if all 1.1 billion smokers worldwide were to switch to a less harmful nicotine replacement product, it could prevent disease and save millions of lives globally. Sweden has found a solution for smokers and we must work together to follow their example and save lives around the world.


This incredible success story sheds light on Sweden's secret to success, where the key factor is an open-minded attitude towards less harmful alternatives to smoking. While snus has long been at the forefront of harm reduction efforts, in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers looking to quit.


Sweden's gradual harm reduction approach differs significantly from the measures proposed by the International Tobacco Control Organization. Advocates for harm reduction in the EU have been pushing for reductions in harm to be included in cancer prevention plans. Despite the fact that the Tobacco Control Framework Convention recognizes harm reduction as a viable option, the World Health Organization continues to refuse to acknowledge its benefits.


Professor Karl Fagerström stated during the event, "Sweden's upcoming presidency of the European Union is a great opportunity to share the country's successful stories, which accounts for 5% of the EU, with other member countries. We hope that Sweden will generously share this knowledge with other nations.


Speakers at the conference emphasized the need for evidence-based and comprehensive tobacco control policies. Therefore, it is imperative to implement the concept of reducing tobacco harm on a broader level to support smoking cessation.


Ensuring that the smoking alternatives with lower health risks are inexpensive, accessible, and easy to use, is a crucial prerequisite for Sweden's success in replicating it in other countries.


The Nicotine Oral Committee is a global nonprofit organization dedicated to assisting governments, health officials, and the public in building knowledge about nicotine oral products, challenging unfounded biases and stereotypes. The organization deals with political, scientific, consumer matters, and related product innovations. Their views are independent of any brand/manufacturer and are tailored to the individual and population health needs of adult smokers.


2FIRSTS will continue to follow and report on this topic. Updates will be available on the 2FIRSTS app. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
From a 2017 Launch to 48% of South Korea’s Heated Tobacco Market, KT&G Looks Back on a Decade of lil
From a 2017 Launch to 48% of South Korea’s Heated Tobacco Market, KT&G Looks Back on a Decade of lil
KT&G announced on Aug. 13, 2026, that it has opened “lil Archive,” a brand exhibition space in Seoul showcasing the evolution, technology platforms and future direction of its heated tobacco brand lil since its launch in 2017. KT&G said lil now spans three major platforms — lil SOLID, lil HYBRID and lil AIBLE — with more than 30 dedicated consumables, and held a 48% share of South Korea's heated tobacco market in the second quarter of 2026. The opening comes as lil enters its 10th year, with KT&G continuing to position the brand for expansion beyond its domestic market.
Aug.14